
- Pharmaceutical Executive-06-01-2008
- Volume 0
- Issue 0
Erik Harris, Elan
S
Erik Harris
Senior Director, Sales and Marketing, Tysabri, Elan
IS BUSY WITH: Newborn twins
BIGGEST ACCOMPLISHMENT: The blockbuster growth of Rituxan
I'm a person that loves challenges," says Erik Harris. And it must be true—otherwise, he wouldn't be heading up the sales and marketing effort for Tysabri and it's new Crohn's Disease indication. "The safety issues, and the fact that patients and doctors have to enroll in a RiskMAP to be on it, make it a difficult product to sell," concedes Harris. "But it's worth it because, for some patients, there are no other options."
Erik Harris
Perhaps even more valuable than his previous work experience building the brands of Rituxan and Tarceva at Genentech, are the lessons Harris learned while serving as a naval aviator for the military. "If you can implement ideas and get people to move forward and change things in that bureaucratic system, well then, those skills translate."
Articles in this issue
almost 18 years ago
Mary Szela, Abbottalmost 18 years ago
Mightier Than the Swordalmost 18 years ago
Keeshia Muhammad, Teva Specialty Pharmaceuticalsalmost 18 years ago
Eric Floyd, Cephalonalmost 18 years ago
Nancy Phelan, Wyethalmost 18 years ago
Tightening the Chainalmost 18 years ago
Kurt Graves, Vertexalmost 18 years ago
Wendy Niebler, Shirealmost 18 years ago
Perfectly ImperfectNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.




